Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Dopamine D(1) receptor binding in the anterior cingulate cortex of patients with obsessive-compulsive disorder.

Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, Scott AM, Norman TR.

Psychiatry Res. 2010 Jul 30;183(1):85-8. doi: 10.1016/j.pscychresns.2010.04.004. Epub 2010 Jun 9.

PMID:
20538439
2.

Quetiapine augmentation in depressed patients with partial response to antidepressants.

Olver JS, Ignatiadis S, Maruff P, Burrows GD, Norman TR.

Hum Psychopharmacol. 2008 Dec;23(8):653-60. doi: 10.1002/hup.970.

PMID:
18816504
3.

Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder.

Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, Scott A, Norman TR.

J Affect Disord. 2009 Apr;114(1-3):321-6. doi: 10.1016/j.jad.2008.06.020. Epub 2008 Aug 15.

PMID:
18706700
4.

Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression?

Keks NA, Burrows GD, Copolov DL, Newton R, Paoletti N, Schweitzer I, Tiller J.

Med J Aust. 2007 Feb 5;186(3):142-4. Review.

PMID:
17309404
5.

Emerging treatments for major depression.

Norman TR, Burrows GD.

Expert Rev Neurother. 2007 Feb;7(2):203-13. Review.

PMID:
17286553
6.
7.

Selective effects of acute serotonin and catecholamine depletion on memory in healthy women.

Harrison BJ, Olver JS, Norman TR, Burrows GD, Wesnes KA, Nathan PJ.

J Psychopharmacol. 2004 Mar;18(1):32-40.

PMID:
15107182
8.

The treatment of depression with different formulations of venlafaxine: a comparative analysis.

Olver JS, Burrows GD, Norman TR.

Hum Psychopharmacol. 2004 Jan;19(1):9-16. Review.

PMID:
14716706
9.

Wine: a scientific exploration.

Burrows GD.

Int J Psychiatry Clin Pract. 2004;8(1):65-6. doi: 10.1080/jpc.8.1.65. No abstract available.

PMID:
24937588
10.

Dual action antidepressants and some important considerations.

Gupta RK, Tiller JW, Burrows GD.

Aust N Z J Psychiatry. 2003 Apr;37(2):190-5. Review.

PMID:
12656958
11.

In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes.

Dodd S, Boulton DW, Burrows GD, De Vane CL, Norman TR.

Hum Psychopharmacol. 2001 Oct;16(7):541-544.

PMID:
12404550
12.

Sertraline in paired blood plasma and breast-milk samples from nursing mothers.

Dodd S, Stocky A, Buist A, Burrows GD, Maguire K, Norman TR.

Hum Psychopharmacol. 2000 Jun;15(4):161-264.

PMID:
12404316
13.

Olanzapine excretion in human breast milk: estimation of infant exposure.

Croke S, Buist A, Hackett LP, Ilett KF, Norman TR, Burrows GD.

Int J Neuropsychopharmacol. 2002 Sep;5(3):243-7. doi: 10.1017/S1461145702003012.

PMID:
12366877
14.

Third-generation antidepressants: do they offer advantages over the SSRIs?

Olver JS, Burrows GD, Norman TR.

CNS Drugs. 2001;15(12):941-54. Review.

PMID:
11735614
15.

Sertraline analysis in the plasma of breast-fed infants.

Dodd S, Stocky A, Buist A, Burrows GD, Norman TR.

Aust N Z J Psychiatry. 2001 Aug;35(4):545-6. No abstract available.

PMID:
11531744
16.

The effect of single oral doses of zopiclone on nocturnal melatonin secretion in healthy male volunteers.

Norman TR, Piccolo J, Voudouris N, Burrows GD.

Prog Neuropsychopharmacol Biol Psychiatry. 2001 May;25(4):825-33.

PMID:
11383979
17.

Subsensitive melatonin suppression by dim white light: possible biological marker of panic disorder.

Nathan PJ, Burrows GD, Norman TR.

Int J Neuropsychopharmacol. 1998 Dec;1(2):115-120.

PMID:
11281954
18.

Pindolol augmentation of antidepressants: a review and rationale.

Olver JS, Cryan JF, Burrows GD, Norman TR.

Aust N Z J Psychiatry. 2000 Feb;34(1):71-9. Review.

PMID:
11185947
19.

Nefazodone in the breast milk of nursing mothers: a report of two patients.

Dodd S, Maguire KP, Burrows GD, Norman TR.

J Clin Psychopharmacol. 2000 Dec;20(6):717-8. No abstract available.

PMID:
11106156
20.

Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography.

Dodd S, Burrows GD, Norman TR.

J Chromatogr B Biomed Sci Appl. 2000 Oct 10;748(2):439-43.

PMID:
11087086
21.

Quality of life and cognitive function of liver transplant patients: a prospective study.

Moore KA, McL Jones R, Burrows GD.

Liver Transpl. 2000 Sep;6(5):633-42.

22.

The effect of gender on the melatonin suppression by light: a dose response relationship.

Nathan PJ, Wyndham EL, Burrows GD, Norman TR.

J Neural Transm (Vienna). 2000;107(3):271-9.

PMID:
10821436
23.

Cade's observation of the antimanic effect of lithium and early Australian research.

Burrows GD, Tiller JW.

Aust N Z J Psychiatry. 1999 Dec;33 Suppl:S27-31.

PMID:
10622176
24.

Melatonin sensitivity to dim white light in affective disorders.

Nathan PJ, Burrows GD, Norman TR.

Neuropsychopharmacology. 1999 Sep;21(3):408-13.

25.

Determination of nefazodone and its pharmacologically active metabolites in human blood plasma and breast milk by high-performance liquid chromatography.

Dodd S, Buist A, Burrows GD, Maguire KP, Norman TR.

J Chromatogr B Biomed Sci Appl. 1999 Jul 9;730(2):249-55.

PMID:
10448960
26.

The effect of age and pre-light melatonin concentration on the melatonin sensitivity to dim light.

Nathan PJ, Burrows GD, Norman TR.

Int Clin Psychopharmacol. 1999 May;14(3):189-92.

PMID:
10435774
27.

Psychotropic drug prescribing: first the good news.

Keks NA, Burrows GD.

Med J Aust. 1999 Apr 5;170(7):293-4. Review. No abstract available.

PMID:
10327966
28.

Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.

Massana J, Möller HJ, Burrows GD, Montenegro RM.

Int Clin Psychopharmacol. 1999 Mar;14(2):73-80.

PMID:
10220121
29.

Effect of the menstrual cycle stage on the melatonin suppression by dim white light.

Nathan PJ, Norman TR, Burrows GD.

Psychoneuroendocrinology. 1999 Feb;24(2):193-200.

PMID:
10101727
30.

Professional training in the practice of hypnosis--the Australian experience.

Stanley RO, Rose L, Burrows GD.

Am J Clin Hypn. 1998 Jul;41(1):29-37.

PMID:
9868815
31.

Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review.

Burrows GD, Maguire KP, Norman TR.

J Clin Psychiatry. 1998;59 Suppl 14:4-7. Review.

32.

Psychiatric illness in women: a review of the function of a specialist mother-baby unit.

Milgrom J, Burrows GD, Snellen M, Stamboulakis W, Burrows K.

Aust N Z J Psychiatry. 1998 Oct;32(5):680-6.

PMID:
9805591
33.

Neurochemical effects of the enantiomers of mirtazapine in normal rats.

McGrath C, Burrows GD, Norman TR.

Eur J Pharmacol. 1998 Sep 4;356(2-3):121-6.

PMID:
9774241
34.

Evidence for 5-HT1A receptor control of pineal melatonin concentrations in the rat.

Nathan PJ, Burrows GD, Norman TR.

Eur Neuropsychopharmacol. 1998 Aug;8(3):183-6.

PMID:
9716310
35.

Psychiatric disorder in HIV infection.

Kelly B, Raphael B, Judd F, Perdices M, Kernutt G, Burrows GD, Burnett PC, Dunne M.

Aust N Z J Psychiatry. 1998 Jun;32(3):441-53.

PMID:
9672736
36.

Modulation of plasma melatonin concentrations by changes in posture.

Nathan PJ, Jeyaseelan AS, Burrows GD, Norman TR.

J Pineal Res. 1998 May;24(4):219-23.

PMID:
9572531
37.

Elevated plasma paroxetine concentrations in a patient treated with a combination of paroxetine and pindolol.

Olver JS, Burrows GD.

Int J Psychiatry Clin Pract. 1998;2(3):225-7. doi: 10.3109/13651509809115361.

PMID:
24940982
38.
39.

Benzodiazepines in anxiety disorders: managing therapeutics and dependence.

Norman TR, Ellen SR, Burrows GD.

Med J Aust. 1997 Nov 3;167(9):490-5. Review. No abstract available.

PMID:
9397065
40.

MJA practice essentials. 3. Assessment of anxiety and depression in primary care.

Ellen SR, Norman TR, Burrows GD.

Med J Aust. 1997 Sep 15;167(6):328-33. No abstract available.

PMID:
9322780
41.

The essential practice of mental health care.

Keks NA, Burrows GD.

Med J Aust. 1997 Aug 4;167(3):147. No abstract available.

PMID:
9269270
42.

Mirtazapine: clinical advantages in the treatment of depression.

Burrows GD, Kremer CM.

J Clin Psychopharmacol. 1997 Apr;17 Suppl 1:34S-39S. Review.

PMID:
9090576
43.

The effect of dim light on suppression of nocturnal melatonin in healthy women and men.

Nathan PJ, Burrows GD, Norman TR.

J Neural Transm (Vienna). 1997;104(6-7):643-8.

PMID:
9444564
44.
45.

Diazepam versus alprazolam for the treatment of panic disorder.

Noyes R Jr, Burrows GD, Reich JH, Judd FK, Garvey MJ, Norman TR, Cook BL, Marriott P.

J Clin Psychiatry. 1996 Aug;57(8):349-55.

PMID:
8752017
46.

Schizophrenia, tardive dyskinesia and essential fatty acids.

Vaddadi KS, Gilleard CJ, Soosai E, Polonowita AK, Gibson RA, Burrows GD.

Schizophr Res. 1996 Jul 5;20(3):287-94.

PMID:
8827855
47.

Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia.

Den Boer JA, van Megen HJ, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG, Burrows GD, Srivastava ON.

Psychopharmacology (Berl). 1995 Oct;121(3):317-22.

PMID:
8584612
48.

Moclobemide for depression: an Australian psychiatric practice study.

Tiller JW, Johnson GF, Burrows GD.

J Clin Psychopharmacol. 1995 Aug;15(4 Suppl 2):31S-34S.

PMID:
7593727
49.

Use of psychotropic drugs in the community.

Keks NA, Burrows GD.

Med J Aust. 1995 Jul 17;163(2):62-3. No abstract available.

PMID:
7616898
50.

Platelet [3H]paroxetine binding in panic disorder.

Maguire KP, Norman TR, Apostolopoulos M, Judd FK, Burrows GD.

J Affect Disord. 1995 Feb 21;33(2):117-22.

PMID:
7759659

Supplemental Content

Loading ...
Support Center